Abemaciclib
A dual inhibitor of cyclin-dependent kinases 4 and 6.
General information
Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor, which is used in cancer therapy. It arrests cell cycle progression in the G1 phase, and thereby inhibits DNA synthesis (NCIt).
Abemaciclib on DrugBank
Abemaciclib on PubChem
Abemaciclib on Wikipedia
Marketed as
VERZENIO
CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles
Preprint Screening |
VERO E6 cell cultures | Jul/11/2020 | ||
|
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Preprint |
Calu-3 human airway epithelial cells | higher IC50 value in Calu-3 cells than VERO E6 cells |
May/12/2020 | |
|
Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors
Small molecule In silico |
in silico | 4.29 | Predicted to non-selectively bind bradykinin receptors, which was theorised to alleviate SARS-CoV-2-related inflammation. |
Sep/21/2020 |
